References
- Potter BK, Burns TC, Lacap AP, Granville RR, Gajewski DA. Heterotopic ossification following traumatic and combat-related amputations. Prevalence, risk factors, and preliminary results of excision. J Bone Joint Surg Am. 2007;89:476-86.
- Sanchez-Duffhues G, Hiepen C, Knaus P, Ten Dijke P. Bone morphogenetic protein signalling in bone homeostasis. Bone 2015;80:43-59.
- Grafe I, Alexander S, Peterson JR, et al. TGF-beta Family Signaling in Mesenchymal Differentiation. Cold Spring Harb Perspect Biol. 2018;10: a022202.
- Kang Q, Song WX, Luo Q, et al. A comprehensive analysis of the dual roles of BMPs in regulating adipogenic and osteogenic differentiation of mesenchymal progenitor cells. Stem Cells Dev. 2009;18:545-59.
- Luu HH, Song WX, Luo X, et al. Distinct roles of bone morphogenetic proteins in osteogenic differentiation of mesenchymal stem cells. J Orthop Res. 2007;25:665-77.
- Wang YK, Sun WF, Liu XG, et al. Comparative study of serum levels of BMP-2 and heterotopic ossification in traumatic brain injury and fractures patients. Zhongguo Gu Shang. 2011;24:399-403.
- Kang H, Dang AB, Joshi SK, et al. Novel mouse model of spinal cord injury-induced heterotopic ossification. J Rehabil Res Dev. 2014;51:1109-18.
- Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004;292:490-5.
- Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modelling and remodelling. Arch Biochem Biophys. 2008;473:139-46.
- Boyce BF, Xing L, Shakespeare W, et al. Regulation of bone remodelling and emerging breakthrough drugs for osteoporosis and osteolytic bone metastases. Kidney Int Suppl. 2003:S2-5.
- Sherman AL, Williams J, Patrick L, Banovac K. The value of serum creatine kinase in early diagnosis of heterotopic ossification. J Spinal Cord Med. 2003;26:227-30.
- Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016;315:801-10.
- Argyropoulou MI, Kostandi E, Kosta P, et al. Heterotopic ossification of the knee joint in intensive care unit patients: early diagnosis with magnetic resonance imaging. Crit Care, 2006;10:R152.
- Yano M, Kawao N, Okumoto K, Tamura Y, Okada K, Kaji H. Fibrodysplasia ossificans progressiva-related activated activin-like kinase signalling enhances osteoclast formation during heterotopic ossification in muscle tissues. J Biol Chem. 2014;289:16966-77.
- Lounev VY, Ramachandran R, Wosczyna MN, Yamamoto M, Maidment AD, Shore EM, et al. Identification of progenitor cells that contribute to heterotopic skeletogenesis. J Bone Joint Surg Am. 2009;91:652-63.
- Scott MA, Levi B, Askarinam A, et al. Brief review of models of ectopic bone formation. Stem Cells Dev. 2012;21:655-67.
- Tanaka H, Nagai E, Murata H, et al. Involvement of bone morphogenic protein-2 (BMP-2) in the pathological ossification process of the spinal ligament. Rheumatology 2001;40:1163-8.
- Suzuki T, Bessho K, Segami N, Nojima T, Iizuka T. Bone morphogenetic protein-2 in temporomandibular joints with internal derangement. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999;88:670-3.
- Zhou N, Li Q, Lin X, et al. BMP2 induces chondrogenic differentiation, osteogenic differentiation and endochondral ossification in stem cells. Cell Tissue Res. 2016;366:101-11.
- Qu X, Chen Z, Fan D, Xiang S, Sun C, Zeng Y, et al. Two novel BMP-2 variants identified in patients with thoracic ossification of the ligamentum flavum. Eur J Hum Genet 2017;25:565-571.
- Yu PB, Deng DY, Lai CS, et al. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med. 2008;14:1363-9.
- Micha D, Voermans E, Eekhoff MEW, et al. Inhibition of TGFbeta signalling decreases osteogenic differentiation of fibrodysplasia ossificans progressiva fibroblasts in a novel in vitro model of the disease. Bone 2016;84:169-180.
- Agarwal S, Loder SJ, Breuler C, et al. Strategic Targeting of Multiple BMP Receptors Prevents Trauma-Induced Heterotopic Ossification. Mol Ther. 2017;25:1974-1987.
- Wu J, Ren B, Shi F, Hua P, Lin H. BMP and mTOR signalling in heterotopic ossification: Does their crosstalk provide therapeutic opportunities? J Cell Biochem. 2019;120:12108-12122.
- Al-Fakhri N, Hofbauer LC, Preissner KT, Franke FE, Schoppet M. Expression of bone-regulating factors osteoprotegerin (OPG) and receptor activator of NF-kappaB ligand (RANKL) in heterotopic vascular ossification. Thromb Haemost. 2005;94:1335-7.
- Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12(9):1260-8.
- Wilkinson JM, Stockley I, Hamer AJ, Barrington NA, Eastell R. Biochemical markers of bone turnover and development of heterotopic ossification after total hip arthroplasty. J Orthop Res. 2003;21:529-34.
- Hudson SJ, Brett SJ. Heterotopic ossification--a long-term consequence of prolonged immobility. Crit Care, 2006;10:174.
- Eastell R, Szulc P. Use of bone turnover markers in postmenopausal osteoporosis. Lancet Diabetes Endocrinol. 2017;5:908-923.
- Fatayerji D, Eastell R. Age-related changes in bone turnover in men. J Bone Miner Res. 1999;14:1203-10.